Skip to main content

Table 2 Observations and tests

From: Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia

 

Eligibility assessment

Protocol treatment

Week

-4 to 0

0

*

8

12

26

52

78

104

Doctor’s check

○

○

○

○

○

○

○

○

○

Height†, body weight

○

    

○

○

○

○

Blood test‡

○

○

 

○

○

 

○

 

○

PANSS§

 

○

○

○

○

○

○

○

○

CGI-SS

○

 

○

○

○

○

○

○

○

CGI-S

 

○

○

      

CGI-I

   

○

○

○

○

○

○

MacCAT-CR|| (if possible)

 

○

       

Social activity (PSP, EQ-5D)

 

○

○

  

○

○

 

○

DIEPSS

 

○

○

○

○

○

○

○

○

Adverse events

  

○

○

○

○

○

○

○

  1. PANSS, Positive and Negative Syndrome Scale; CGI-SS, Clinical Global Impression-Suicide Scale; CGI-S, Clinical Global Impression-Severity; CGI-I, Clinical Global Impression-Improvement; MacCAT-CR, MacArthur Competence Assessment Tool for Clinical Research; PSP, Personal and Social Performance Scale; EQ-5D, Euro Quality of life-5 dimension; DIEPSS, Drug-Induced Extrapyramidal Symptoms Scale.
  2. In case of study discontinuation, all observations and tests except for MacCAT-CR will be performed.
  3. * At the time of start of single-drug therapy.
  4. † Measured only at the time of eligibility assessment.
  5. ‡ Cr (serum creatinine), HbA1c (glycohemoglobin A1c),WBC, RBC, hemoglobin, hematocrit, platelet count, AST (aspartate aminotransferase), ALT (alanine aminotransferase), CK (creatine kinase), blood glucose, prolactin.
  6. § Remission is evaluated in accordance with the Andreasen definition (rating below mild on all 8 items of the PANSS for 6 consecutive months or more).
  7. || Assessed at the latest by Week 12.
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us